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Abstract 
In healthcare, applying deep learning models to electronic 
health records (EHRs) has drawn considerable attention. EHR 
data consist of a sequence of medical visits, i.e. a multivariate 
time series of diagnosis, medications, physical examinations, 
lab tests, etc. This sequential nature makes EHR well matching 
the power of Recurrent Neural Network (RNN). In this paper, 
we propose “Deep Diabetologist” – using RNNs for EHR 
sequential data modeling, to provide the personalized 
hypoglycemia medication prediction for diabetic patients. 
Particularly, we develop a hierarchical RNN to capture the 
heterogeneous sequential information in the EHR data. Our 
experimental results demonstrate the improved performance, 
compared with a baseline classifier using logistic regression. 
Moreover, hierarchical RNN models outperform basic ones, 
providing deeper data insights for clinical decision support. 
Keywords:  
Clinical Decision Support, Machine Learning, Neural 
Networks, Electronic Health Records 
Introduction 
From a global report on diabetes [1], over 422 million adults 
have been diagnosed with diabetes, by 2014. In China, there 
have been 114 million adults suffering from diabetes, by 2013 
[2]. Roughly estimated, in China, a typical endocrinology visit 
in the outpatient clinic has only 5-10 minutes, and often, a 
diabetologist may see up to 50 patients in a single morning [3]. 
Diabetes is a chronic disease, and hypoglycemia medications 
need to be timely adapted according to the clinical conditions. 
Most Chinese diabetic patients go to hospitals, regularly 
(generally 2-4 weeks) for prescribing the hypoglycemia 
medications. Facing such a large scale of diabetic patients, but 
with a very limited coverage of diabetologists in China, is there 
any way to learn to prescribe hypoglycemia medications by 
deep learning from data (so as to provide clinical decision 
support for diabetologists)? 
To answer this question, we need two key points. One is what’s 
the data, and the other is what’s the learning framework. 
Luckily, with the development of regional health information 
systems in China, Electronic Health Record (EHR) repositories 
have been growing up with a great amount of longitudinal 
patient visits [4]. Taking a level 2 city in China as an example, 
there have been 3.6 million patients documented in her EHR 
repository, having a time window from 2006 to present (over 
10 years). Undoubtedly, advanced deep learning models are 
expected to shed light on the meaningful use of EHR. 
Considering that EHR data consist of multivariate time series 
of observations (such as diagnosis, medications, physical 
examinations and lab tests), the well-matched deep learning 
framework is Recurrent Neural Network (RNN). RNN captures 
the sequential nature of EHR data, and recently there have been 
at least three remarkable representatives on applying RNNs to 
EHR data analysis. In [5], Lipton et al. used Long Short-Term 
Memory (LSTM, one of RNN implementations) to predict 
diagnosis codes in the pediatric intensive care unit. Their 
network input was a vector of 13 physical examinations and lab 
tests, for training a LSTM model to classify 128 diagnosis 
codes. In [6], Choi et al. used Gated Recurrent Units (GRU, one 
of RNN implementations) to predict both the diagnosis codes 
and the medication codes, as well as the time duration until next 
visit, among primary care patients. Their network input was a 
vector of 38,594 diagnosis and medication codes, for training a 
GRU model to classify 1,183 diagnosis codes and 595 
medication codes, plus a regression of the time duration 
between visits. A more clinically meaningful exploration is [7], 
which again used GRU to demonstrate the improved model 
performance in predicting initial diagnosis of heart failure. 
Related works have well proved the RNN power on EHR data 
analysis, however, we observed that EHR data have not been 
completely exploited in previous works. For example, the real-
valued physical examinations and lab tests were used in [5] but 
not in [6][7]. Conversely, the discrete diagnosis and medication 
codes were used in [6][7] but not in [5]. Fortunately, both real-
valued measurement variables and discrete code variables have 
been documented in our EHR repository, and in Figure 1, we 
illustrate the sample data for a given patient, sorted by date. For 
instance, on 2015-06-15, this patient had records about fasting 
plasma glucose (FPG) valued as 8.13 mmol/L, was diagnosed 
with diabetes (using ICD 10 code of E14), and was prescribed 
with biguanides (as hypoglycemia drug).  
 
 
 
 
 
 
 
 
Figure 1. A sample patient data from EHR repository. 
Observing that time series in EHR data could be layered by 
different types, e.g. in Figure 1, the bottom layer is for clinical 
measurements, the middle layer is for diagnoses, and the top 
layer is for medications, we propose to leverage the hierarchical 
recurrent neural network (HRNN) framework for a better multi-
resolution learning. Intuitively, a series of clinical 
measurements might be targeted to some diagnosis, while a 
series of diagnoses (plus a series of clinical measurements) 
might be targeted to some medication. In literature, HRNN has 
been proposed and implemented for computer vision [8], 
natural language processing [9], dialogue response generation 
[10], etc. However, to the best of our knowledge, HRNN has 
not been used for EHR data analysis yet. 
2015-06-15 2015-07-08 2015-08-24 Timeline 
Physical	examination		
/Laboratory	test 
Diagnosis	(Dx) 
Medication	(Rx) 
FPG:	8.13	mmol/L 
SBP:	148	mmHg 
DBP:	96	mmHg 
I10:	Hypertension E14:	Diabetes 
Biguanides 
HbA1c:	7.8% 
E14:	Diabetes 
Biguanides 
Sulfonylureas 
In this paper, we explore to build RNN in a hierarchical way for 
hypoglycemia medication prediction, and we name “Deep 
Diabetologist” which is a cognitive decision advisor to provide 
clinical decision support for treatment recommendation. 
Methods 
Before diving into the details of learning techniques, we first 
need to do EHR data preprocessing including cleansing and 
imputation. Then, we will introduce the learning framework of 
“Deep Diabetologist”, including the basic and hierarchical 
RNN medication prediction models. 
Data Preprocessing 
As shown in Figure 1, we access to an EHR repository 
consisting of several relational tables (including a diagnosis 
table, a medication table, a physical examination table, a lab test 
table, etc.) with association of patient IDs and event IDs.   
In the medication table, 745 distinct drug brand names with 
production batches are documented, and for non-commercial 
purpose, we will map them to the higher level drug classes. By 
definition of a drug taxonomy (after consulting domain 
experts), they are mapped into 7 hypoglycemia drug classes: 
Biguanides, Sulfonylureas, Glinide, Thiazolidinediones (abbr. 
TZDs), Alpha-glucosidase inhibitors (abbr. AGIs), Dipeptidyl 
peptidase-4 (abbr. DPP-4), and Insulin.  
In the diagnosis table, there are 27,258 distinct ICD 10 codes 
used (e.g. E11.901 and E11.902). Considering the first 3-digit 
of an ICD 10 code (e.g. E11) is representative for a specific 
disease, we extract out 1,419 distinct 3-digit ICD 10 codes. 
Figure 2 is the scatter plot of these 1,419 codes, where the x-
axis represents the codes and the y-axis represents the number 
of medical visits having the codes. Clearly, it is a long-tail 
distribution, and we catch the 350 most-frequently used ones as 
the diagnosis codes in our experiments (since those less used 
ones might introduce noise in the data).  
 
Figure 2. A scatter plot of ICD codes. 
Also, we conduct data cleansing for the physical examination 
and lab test tables, leaving only 124 measurement codes. Not 
surprisingly, this vector of 124 variables has quite a lot missing 
values, because not every medical visit needs to do all of the 
measurements. Similar to the work of [5], we do imputation, 
but differently, we have no such clinically normal values as 
defined by domain experts for these all 124 variables. 
Therefore, we first normalize each variable 𝑥, i.e. rescaled to 
the standard deviation: 𝑥′ = $%&'  where 𝜇  is the mean of the 
population, and 𝜎 is the standard deviation of the population. 
Next, we impute zero for missing values, since after 
normalization, zero is for the mean of the population. That is, 
when a variable value is missing, we assume it as the mean. 
Next, we define the cohort as diabetic patients, and the studied 
cases consist of outpatient hypoglycemia medications. For 
experiments, 21,796 patients are selected into our cohort, 
satisfying the following 3 criteria: (1) they are city residents 
(assuming a city-level EHR repository has continuous records 
for city residents); (2) they have been diagnosed with diabetes 
(i.e. documented by ICD 10 codes of E10, E11, E12, E13, E14); 
(3) they have sequential hypoglycemia medications of length 
more than 10 from 2006 to present (towards a better RNN 
sequence learning). Table 1 shows the medical visit numbers of 
diagnoses, medications and measurements, by counting per 
day, per patient (and per code), for the cohort of 21,796 patients. 
Table 1. Statistics of medical visits 
 Counting per day,  
per patient, per code 
Counting per day, 
per patient 
Diagnosis 4,154,756 3,371,287 
Medication 805,477 620,633 
Measurement  781,501 81,294 
The number of visits with diagnosis codes is over 4 million, and 
by aligning the different diagnosis codes within one day for one 
patient, we still get more than 3 million. The number of visits 
with medications is smaller (because only hypoglycemia medi-
cations are counted in), and by average, there are 28.5 medica-
tions for a diabetic patient.  A weird issue is the quite small size 
of clinical measurements. By the patient-day alignment, the av-
erage number of visits with clinical measurements is only 3.7. 
After consulting local physicians and patients in the city, we 
understand this as a common situation: for a chronic disease 
like diabetes, most patients go to visit physicians, esp. in com-
munity hospitals, regularly (generally 2-4 weeks) for prescrib-
ing the medications without any clinical measurement. It was 
said, by policy, the prescription interval at community hospitals 
has been limited to at most 1 month.  
Table 2. Statistics of using previous medications 
Previously prescribed == null 21,796 
Previously prescribed <> currently prescribed 198,153 
Previously prescribed == currently prescribed 400,684 
Total 620,633 
Then, we have to pay special attention to an important factor in 
our scenario – the previously prescribed drug classes! As shown 
in Table 2, for our 620,633 medications (after the patient-day 
alignment), there are 400,684 cases prescribed as the same as 
previously, resulting in an accuracy of 400684/620633=0.6456. 
Row 1 in Table 2 reports 21,796 cases, each of which corre-
sponds to the first prescription of each patient in the cohort.  
Table 3. Statistics of hypoglycemia drug classes 
 Number Ratio 
Biguanides 141,900 0.2286 
Sulfonylureas 88,995 0.1434 
Glinide 87,255 0.1406 
TZDs 20,317 0.0327 
AGIs 163,972 0.2642 
DPP-4 939 0.0015 
Insulin 302,099 0.4868 
Finally, Table 3 is presented to show the imbalance of cases 
being prescribed with different hypoglycemia drug classes, 
where Ratio=Number/TotalNumber (and the TotalNumber is 
620,633). Insulin is the most frequently used hypoglycemia 
drug class, followed by AGIs and Biguanides, while DPP-4 is 
rarely used in our cohort. 
Learning Framework 
As its name implies, “Deep Diabetologist” is a cognitive 
decision advisor who has deep insights by learning from 
longitudinal EHR data to provide personalized hypoglycemia 
medication predictions for diabetic patients. In this respect, we 
need to clarify (1) what to learn, and (2) how to learn. 
In real life, for diabetic patients whose blood glucose has not 
been well controlled, two or more hypoglycemia drug classes 
are often combined together as medications. Recalling to Figure 
1, on 2015-08-24, that patient was prescribed with biguanides 
plus sulfonylureas. By counting the number of distinct drug 
combinations, we get the number of 85 (theoretically, the 
combination number could be 27－1 = 127, but not all drug 
combinations are clinically meaningful).  
Table 4. Classification problem for predicting medications 
Problem Binary  
Classification 
Multiclass  
Classification 
BCDC BCDCC MCDC MCDCC 
# of classifiers 7 85 1 1 
# of classes 1 1 7 85 
Multiple label? No No Yes No 
Evaluation AUC Accuracy AUC Accuracy 
  
Now, the problem comes – which type of classification problem 
should we formulate? Table 4 lists the different classification 
problems for predicting medications, where # of classifiers 
means the number of classifiers to be trained, and # of classes 
means the number of classes to be labeled. In this paper, we will 
present our experimental results for the multiclass classification 
problem (in bold): one classifier for 7 drug classes (as denoted 
as MCDC) and the other classifier for 85 drug combination 
classes (as denoted as MCDCC). In real clinical settings, some 
junior physicians, such as general practitioners, are more 
interested in MCDCC which predicted results – after the final 
confirmation – could be directly fed into the computerized 
physician order entry (CPOE). However, for some senior 
physicians, such as specialists, might be more interested in 
MCDC, which predicted results need the final decision for 
combination and then to be fed into CPOE. Therefore, we keep 
experiments for both MCDC and MCDCC, while leaving the 
binary classification problems for future work. 
RNN medication prediction model 
We start by defining a recurrent neural network medication 
prediction model (namely, RNN_MPM), referring to the well-
established recurrent neural network language model [11]. 
The RNN_MPM is a probabilistic generative model, with 
parameters 𝜃 which decomposes the probability over medical 
visits 𝑣,, … , 𝑣/: 𝑃1 𝑣,, … , 𝑣/ = 𝑃1 𝑣2|𝑣,, … , 𝑣2%,/24,  
For the one-label problem MCDCC, the parameterized 
approximation of the output distribution uses an RNN with a 
softmax layer on the top, where dcc (or dcc’) is one of the 85 
drug combination classes: 𝑃1 𝑣25, = 𝑑𝑐𝑐|𝑣,, … , 𝑣2 = exp 𝑔 ℎ2, 𝑑𝑐𝑐 exp 𝑔 ℎ2, 𝑑𝑐𝑐=>??@  
For the multi-label problem MCDC, the parameterized 
approximation of the output distribution uses an RNN with 
multiple sigmoid layers on the top, where dc is one of the 7 drug 
classes: 𝑃1 𝑣25, = 𝑑𝑐|𝑣,, … , 𝑣2 = 1 1 + exp −𝑔 ℎ2, 𝑑𝑐  
For both MCDCC and MCDC, f is the hidden state update 
function, which we will assume is either an LSTM gating unit 
[12] or a GRU gating unit [13]. In this paper, we will use the 
LSTM gating unit for experiments. ℎ2 = 𝑓 ℎ2%,, 𝑣2  
The function g is the dot product of hn and dc (or dcc), where 
dc is a multi-hot vector of the 7 drug classes, and dcc is a one-
hot vector of the 85 drug combination classes.  
Figure 3 shows a basic RNN medication prediction model in 
our scenario, where the output Y is, either a multi-hot vector of 
the 7 drug classes for MCDC, or a one-hot vector of the 85 drug 
combination classes for MCDCC, and the subscript k means the 
kth time step. For the input, X is a vector of multivariate values, 
including real values (for physical examinations and lab tests) 
and binary values (for diagnosis codes and previously 
prescribed drug classes). 
 
 
 
 
 
 
 
 
 
Figure 3. A basic RNN medication prediction model. 
Here, we use an aggregation function, Xk=agg(Xk,1, …, Xk,mk). 
In fact, the kth time step has an observed medication, and from 
the (k-1)th time step to the kth time step, there is no medication 
observed, but there could be other observations like diagnoses, 
physical examinations and lab tests. Recalling to Figure 1, the 
(k-1)th time step was 2015-06-15 using biguanides, the kth time 
step was 2015-08-24 using biguanides plus sulfonylureas, and 
on 2015-07-08, the patient had blood pressure measurements 
with diagnosis of hypertension but without any hypoglycemia 
medication. Therefore, we collect all observations at every time 
step, and Xk,1, …, Xk,mk are meant to be mk time steps sandwiched 
between the (k-1)th medication and the kth medication. These 
vector values will be aggregated by a function (e.g. average, 
maximum, count), to be input at the kth time step. 
HRNN medication prediction model 
Following up, we naturally wonder whether we can leverage a 
hierarchical RNN framework for modeling the sandwiched 
time steps, as shown in Figure 4. For the upper RNN layer, its 
output definition is the same as in Figure 3, while its input is 
the output from a lower RNN layer. For the lower RNN layer, 
its input is now the vector at each sandwiched time steps, Xk,1, 
…, Xk,mk, whose output will be input to the upper RNN layer.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. A hierarchical RNN medication prediction model. 
Figure 5 shows a more complicated model, where the input of 
the upper RNN layer is now a merge of multiple outputs from 
lower RNN layers. This somehow matches our intuition, if we 
… 
Yk-1 
Xk-1=	
agg(Xk-1,1,	…	,	Xk-1,mk-1) 
Yk 
Xk=	
agg(Xk,1,	…,	Xk,mk) 
… 
… Yk-1 
Xk,1 
Yk 
… 
… 
XK,mk
 Xk-1,1 
… 
XK-1,mk-1
 
regard the green RNN layer as learning clinical measurements, 
and the yellow RNN layer as learning diagnoses, then such a 
hierarchical RNN model is to predict medications based on an 
abstract representation by learning from multi-modality 
sequences of clinical measurements and diagnoses. 
 
 
 
 
 
 
 
 
 
 
Figure 5. A hierarchical RNN model with multiple layers. 
Here, we claim, although HRNN has been proposed and 
implemented in domains such as natural language processing 
and computer vision [8][9][10], the HRNN application for 
predicting medications is firstly investigated in this paper, 
which deeply explores the heterogeneity of EHR data in 
multivariate time series. 
Results 
For experiments, we use a cohort of 21,796 patients (as 
introduced in the section of Data Preprocessing) from an EHR 
repository of a level 2 city in China. The cases to be studied are 
outpatient hypoglycemic prescriptions after the firstly observed 
diabetes diagnosis, where a case is counted per day per patient, 
and the number of cases is 620,633. All models are trained on 
80% of the cohort and validated on 10%, remaining 10% for 
testing. Table 5 is an overview of the experimental dataset. 
Table 5. Overview of dataset 
 Number of patients Number of cases 
Training  17,436 496,252 
Testing 2,180 62,497 
Validation  2,180 61,884 
Total 21,796 620,633 
 
Our experiments are not meant to verify the RNN power, which 
has been well shown up in related works, e.g. [5][6][7]. Instead, 
we are more interested in a practical model which could be ap-
plied, in real clinical settings, to provide decision support. So, 
we do experiments using different (basic/hierarchical) variants 
of RNN models to address the multi-class problems for predict-
ing either multiple labels of the 7 drug classes (a.k.a., MCDC) or 
one label of the 85 drug combination classes (a.k.a., MCDCC).  
In this paper, LSTM is applied to implement the RNN, on a 
machine configured with GPU using Theano backend. We train 
each LSTM for 20 epochs (actually, we have observed the 
convergent results after 10 epochs), and to avoid overfitting, we 
stack a dropout (of 0.5) layer before the last Dense layer of the 
output vector. Besides, to address the variable-length inputs to 
RNN, we set a maximal length of 20 for input (if an instance 
has length less than 20, then we will mask the rest as 0), and a 
masking layer with mask value of 0. All hidden layers are set 
up with 64 cells, and the batch size is 32. 
Experiment 1: with previous medications 
As mentioned above, in real life, the prescriptions are often the 
same as before. Therefore, for the first experiment, we will 
compare our (H)RNN models with the baseline, assuming 
previous medications are available for the input. Then, we will 
conduct a second experiment, when previous medications are 
absent for the input. 
In Experiment 1, we have 4 predictors: Prev., LR, RNN and 
HRNN. The Prev. uses the previous medication for the current 
prediction. LR (Logistic Regression), as usual, is the best 
candidate for a baseline classifier, with input of 
481=350+124+7 variables, where 350 is the number of ICD 
codes, 124 is the number of clinical measurements, and 7 is the 
number of previously used drug classes. RNN and HRNN are 
defined as above, where RNN has the same 481 variables for 
the input at every time step (referring to Figure 3), and HRNN 
has an upper layer of 7 drug classes with merge of the outputs 
from two lower layers (referring to Figure 5), where one layer 
(in yellow) inputs a vector of 350 ICD codes and the other layer 
(in green) inputs a vector of 124 clinical measurements. 
Table 6 and Table 7 are results for the multi-label problem 
MCDC and the one-label problem MCDCC, respectively. In Table 
6, AUC is the area under the curve, and we report the AUC 
scores for 7 drug classes as well as the average. In Table 7, 
accuracy = #Hit/#Sample, where #Hit is the number of cases in 
which the predicted label equals to the targeted label, and 
#Sample is the number of samples. Moreover, we separately 
report the different accuracy results for those head cases, tail 
cases, and all cases – the head case means the first medication 
of a patient’s sequence, and the tail case means the last 
medication of a patient’s sequence, while the average is 
calculated for all cases of a patient’s sequence. The head 
accuracy of Prev. is not available, since there is no previously 
prescribed medication to count in for the head case. 
Table 6. AUC results for MCDC in Experiment 1 
 Prev. LR RNN HRNN 
Biguanides 0.8630 0.8928 0.9252 0.9259 
Sulfonylureas 0.8798 0.9210 0.9428 0.9433 
Glinide 0.8426 0.8676 0.9326 0.9339 
TZDs 0.8245 0.8481 0.9169 0.9229 
AGIs 0.8541 0.8305 0.9104 0.9133 
DPP-4 0.8823 0.8761 0.9058 0.9051 
Insulin 0.9164 0.8905 0.9422 0.9435 
Average 0.8661 0.8752 0.9251 0.9268 
Table 7. Accuracy results for MCDCC in Experiment 1 
 Prev. LR RNN HRNN 
Head  -- 0.2963 0.3417 0.3436 
Tail  0.6772 0.6986 0.7060 0.7067 
Average 0.6456 0.6693 0.6733 0.6745 
  
Remarkably, results of Prev. are quite high – by average, the 
accuracy is 0.6456 and the AUC is 0.8661. The performance of 
LR is slightly improved, by comparison of Prev. Our RNN and 
HRNN both outperform Prev. and LR. From HRNN to RNN, 
the performance is increased (as shown in bold), except the 
AUC score of DPP-4. We argue that’s because of the very 
limited number of DPP-4 cases (referring to Table 3). 
Experiment 2: without previous medications 
Next, we have only 3 predictors: LR, RNN and HRNN, since 
that we assume previous medications are not available for the 
input – This experiment is meant to remove the “big plays” of 
previous medications. 
Similar to Experiment 1, LR is still the baseline classifier, with 
input of 474=350+124 variables, where 350 is the number of 
ICD codes, and 124 is the number of clinical measurements. 
… … 
Yk-1 Yk … 
… … … 
RNN has the same 474 variables for the input at every time step 
(referring to Figure 3), and HRNN has an upper layer with no 
raw data input from those 7 drug classes, but only a merge of 
the outputs from two lower layers (referring to Figure 5). 
Results for MCDC and MCDCC are reported in Table 8 and Table 
9, respectively. Both RNN and HRNN outperform the baseline 
LR. The performance of HRNN is slightly higher than that of 
RNN, and again, the AUC score of DPP-4 is the exception.  
Table 8. AUC results for MCDC in Experiment 2 
 LR RNN HRNN 
Biguanides 0.6254 0.7088 0.7091 
Sulfonylureas 0.6095 0.6328 0.6421 
Glinide 0.5774 0.5967 0.6115 
TZDs 0.5184 0.6013 0.6058 
AGIs 0.5766 0.5548 0.5698 
DPP-4 0.7703 0.7269 0.7043 
Insulin 0.5855 0.6475 0.6520 
Average 0.6090 0.6384 0.6421 
Table 9. Accuracy results for MCDCC in Experiment 2 
 LR RNN HRNN 
Head  0.2932 0.3404 0.3408 
Tail  0.3454 0.3477 0.3495 
Average 0.3484 0.3480 0.3509 
Discussion 
Deep learning techniques have been successfully applied to var-
ious fields, such as computer vision, natural language pro-
cessing, speech and image recognition. In healthcare domain, 
the disease risk model was deeply trained in [7], clinical phe-
notypes were incrementally discovered in [14], and [15] pro-
posed a general-purpose patient representation from EHR data. 
Our work follows this trend, and our experimental results 
demonstrate the use of (hierarchical) recurrent neural networks 
to model sequential events in EHR data would provide deep ev-
idence for treatment recommendation. 
However, we have to admit our limitations. First, the improve-
ment from HRNN to RNN is not exciting, and we owe that to 
the serious shortage of clinical measurements in our EHR re-
pository. For our proposed HRNN models (referring to Figure 
5), we have a lower RNN layer with input of sequential clinical 
measurements, and the scarcity of clinical measurements un-
doubtedly makes our HRNN models less effective. Second, in 
HRNN implementation, we simply concatenate the hidden 
states from lower RNN layers, and more advanced merge func-
tions should be considered in future. Third, from Experiment 1 
to Experiment 2, the total performance is decreased, which 
again proves the strength of prescribing as previously. An in-
teresting ongoing work is to use our current (H)RNN models to 
implement a binary classifier to predict the prescription change 
– that is, the outputs of Figure 3,4,5 become binary values (1 
for prescription being changed, 0 for prescription being un-
changed), while still using the inputs as defined above. 
Conclusions 
“Deep Diabetologist” is named for our work, and the rationale 
behind this naming is to provide clinical decision support, by 
deep learning from the longitudinal EHR data. In this paper, we 
propose basic and hierarchical RNN medication prediction 
models, and by experiments, we demonstrate the improved per-
formance of predicting hypoglycemia medications for diabetic 
patients. In particular, we pave the way for using the hierar-
chical RNN framework for EHR data modeling.  
Admittedly, our current work of “Deep Diabetologist” is a na-
ïve learner, without any ability to distinguish good and bad clin-
ical outcomes. Instead, the goal of clinical decision support is 
to improve outcome, and how to train our “Deep Diabetologist” 
towards good outcomes is still a long way to go. 
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